IVIEW Therapeutics’ CEO Dr. Bo Liang chaired a Roundtable at the First International Alliance for Ophthalmology Innovation (IOAI) Forum

[Salt Lake City, Utah, USA, May 5, 2025] During the 57th Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2025), the International Alliance for Ophthalmology Innovation (IOAI) held the first IOAI Forum@ARVO at the Utah State Capitol Rotunda, focusing on how to leverage US and China resources for ophthalmology innovations. This forum has built a high-level communication platform across scientific research, industry, venture capital and clinical practice , attracting diverse representatives from the global ophthalmic innovation ecosystem, including ophthalmic start-ups and technology innovators, clinical researchers in both US and China, R&D and business development executives of multinational ophthalmic companies, professional investors in the ophthalmic field, and contract research and manufacturing service organizations (CRO/CDMO). The roundtable II of this forum was chaired by Dr. Bo Liang, CEO of IVIEW Therapeutics Inc. He connected the views and practical experiences of the panelists with his in-depth and forward-looking guiding style. The theme of the forum was "Leveraging US and China Resources for Ophthalmology Innovations". Dr. Shen Wang, CEO of Viva Vision, Dr. Jing-Feng Huang, CEO of Seinda Pharmaceutical Corporation, Dr. Yuan Chang, International Business Development Director of China Eye Valley, Jeanette Stewart, CEO of PRN Pharmaceutical Research Network, and Dr. Gavin Spencer, CEO of Nicox SA, were invited to participate in the roundtable discussion. In the context of the challenges and reshaping of global scientific and technological cooperation, the panelists had in-depth discussions on how to achieve complementary advantages, promote resource synergy and accelerate innovation between the two important geo-economic regions of China and the United States. The discussion covered the technical difficulties and opportunities of different treatment modes such as small molecules, antibody/protein drugs and gene therapy in China and the United States, starting from the CMC strategy, preclinical research, to clinical development and regulatory strategies. At the regulatory level, panelists shared the different strategies between FDA and NMPA, especially the policy evolution in emerging technologies, innovative therapies and clinical trial design. In addition, combined with the "clinical trial + real-world research" model, experts discussed how to accelerate the acceptance of multi-national data and market access efficiency while improving the quality of evidence. In terms of the policy environment, the potential impact of the recent US Biosecurity Act has also become a focus. Finally, the forum discussed the impact of the current investment and capital market environment in China and the United States on innovative ophthalmic companies. The panelists agreed that in the current complex and changing international market and the increasingly cautious financing situations, companies can achieve US and China collaborations and resource integrations through flexible allocation of regional resources, optimization of clinical design, and pro-active communications with both US and China regulatory agencies, which are still the key driving forces for promoting efficient ophthalmic innovation. Dr. Liang presented the latest progresses of IVIEW's innovative research during the roadshow. Among the five leading innovative ophthalmic drug R&D pipelines at IVIEW, three projects have achieved breakthrough progress recently: ✓ The IVW-1001 project, a NCE innovative drug with a novel target TRPM8 agonist for the treatment of dry eye disease (DED) has completed the Phase 1/2 clinical trials and achieved positive top-line results. IVIEW has now finalized the Phase 3 clinical study plan and plan to meet with FDA soon. It is expected to start the Phase 3 pivotal clinical trials in early 2026; ✓ IVIEW-1201/IVIEW-1201D, the first broad-spectrum eye-drop for the treatment of viral and bacterial conjunctivitis, has completed Phase 2 clinical studies and is expecting FDA’s agreement on phase 3 pivotal study plans in May 2025; ✓ The IVW-2001 project, a novel gene therapy for glaucoma treatment, has gained IRB approval for IIT trial and is expecting to enroll the first patient soon.

The release as fetched from its publisher. iviewtherapeutics.com ↗